Skip to main content
. Author manuscript; available in PMC: 2022 Jun 19.
Published in final edited form as: Br J Haematol. 2017 Nov 28;183(5):815–819. doi: 10.1111/bjh.15036

Fig 1.

Fig 1.

The overall survival was significantly different in myelodysplastic syndromes (MDS) patients classified according to the (A) Revised International Prognostic Scoring System (IPSS-R; Greenberg et al, 2012), (B) Makishima model (Makishima et al, 2017) and (C) Nazha model (Nazha et al, 2016) as shown by the Kaplan–Meier method.